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1 |  INTRODUCTION
The availability of a wearable artificial kidney (WAK) for 
patients with end- stage kidney disease (ESKD) has been 
long- awaited. Such a device would facilitate more frequent or 
continuous dialysis outside the hospital, improving patient's 
health and quality of life.1 Miniaturization of the hemodial-
ysis (HD) machine and peritoneal dialysis (PD) technology 
is based on the continuous regeneration of a small volume 
of dialysate in a closed- loop system.2 The major challenge 
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Abstract
A major challenge for the development of a wearable artificial kidney (WAK) is the 
removal of urea from the spent dialysate, as urea is the waste solute with the highest 
daily molar production and is difficult to adsorb. Here we present results on glu-
cose degradation products (GDPs) formed during electrooxidation (EO), a technique 
that applies a current to the dialysate to convert urea into nitrogen, carbon dioxide, 
and hydrogen gas. Uremic plasma and peritoneal effluent were dialyzed for 8 hours 
with a WAK with and without EO- based dialysate regeneration. Samples were taken 
regularly during treatment. GDPs (glyoxal, methylglyoxal, and 3- deoxyglucosone) 
were measured in EO- and non- EO- treated fluids. Glyoxal and methylglyoxal con-
centrations increased 26- and 11- fold, respectively, in uremic plasma (at [glucose] 
7 mmol/L) and 209- and 353- fold, respectively, in peritoneal effluent (at [glucose] 
100 mmol/L) during treatment with EO, whereas no change was observed in GDP 
concentrations during dialysate regeneration without EO. EO for dialysate regenera-
tion in a WAK is currently not safe due to the generation of GDPs which are not 
biocompatible.
K E Y W O R D S
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is the removal of urea from the spent dialysate, as urea is the 
waste solute with the highest daily molar production (240- 
470 mmol/d3,4) and is difficult to adsorb.5 Currently, no ef-
ficient urea removal strategy is available that allows for the 
realization of a WAK <2.0 kg that can easily be carried by 
patients for a number of hours per day.5 Several miniature 
artificial kidney devices for HD and PD are under develop-
ment which is based on enzymatic hydrolysis of urea by ure-
ase or urea adsorption by activated carbon (AC).6 However, 
these systems are still relatively large (>5 kg including the 
daily amount of sorbents and dialysate) and do not allow for 
further miniaturization. Therefore, electrooxidation (EO) is 
being explored as an alternative strategy to efficiently remove 
urea from dialysate.2
EO is a technique that applies a current to the dialysate 
to oxidize urea into nitrogen, carbon dioxide, and hydrogen 
gas, either directly at the anode or indirectly in the bulk solu-
tion via hypochlorite that is produced by oxidation of chlo-
ride ions.7,8 EO offers the prospect of reducing the size and 
weight of a WAK to wearable proportions, as the electrodes 
are small, lightweight, stackable, and can be reused. We pre-
viously demonstrated that clinically relevant urea removal 
could be achieved in vitro and in vivo when using EO for the 
regeneration of spent dialysate.2,9 However, a disadvantage 
of EO is the formation of toxic oxidative by- products, such as 
free chlorine (hypochlorous acid and hypochlorite) and bound 
chlorine (chloramines and chlorinated organic compounds), 
ammonium (due to hydrolysis of nitrogenous organic com-
pounds), and other (potentially toxic) unknown compounds. 
We previously showed that free and bound chlorine release 
could be reduced to levels below the maximum acceptable 
levels (as defined by the Association for the Advancement 
of Medical Instrumentation [AAMI] standards for dialysate 
in HD) by using graphite electrodes combined with AC at a 
current of 3 A.9,10 Ammonium release could be reduced by 
the placement of AC and a cation exchanger downstream of 
the EO unit to capture ammonium.9 However, it is unknown 
whether other potentially toxic compounds are formed that 
are not removed by AC.
Preliminary biocompatibility studies suggest that ox-
idative status, cell viability, and cell migration are not im-
paired after exposure to uremic plasma that has been dialyzed 
against electrochemically regenerated dialysate in vitro11 
(Supporting Information: wound closure assay, Figure S1A). 
However, a decline in endothelial cell migration was ob-
served after exposure to peritoneal effluent that was treated 
with EO (Figure S1B). Since glucose concentrations in peri-
toneal effluent are considerably higher (~10- 15 fold) com-
pared with plasma, we hypothesized that the formation of 
glucose degradation products (GDPs) may be responsible for 
this. GDPs are highly reactive carbonyl compounds that are 
associated with oxidative stress, progression of atherosclero-
sis and cardiovascular disease, and mortality in patients with 
diabetes12- 15 and could theoretically be formed during the ox-
idation of carbohydrates in the dialysate.
The aim of this study was to measure three prototyp-
ical GDPs (glyoxal [GO], methylglyoxal [MGO], and 
3- deoxyglucosone [3- DG]) in EO- treated uremic plasma and 
EO- treated peritoneal effluent.
2 |  METHODS
2.1 | Materials
A prototype wearable dialysis device was designed, con-
sisting of a blood and dialysate circuit as described.2 The 
dialysate circuit contained an EO unit with 13 graphite elec-
trodes with a cumulative surface area of 900 cm2, 150 g of 
poly(styrene- divinylbenzene) (PS- DVB) sulfonate beads, 
and 75  g of iron oxide hydroxide beads for respective re-
moval of potassium and phosphate. The EO units with sor-
bents, active carbon, and a degassing unit were provided by 
Nanodialysis (Oirschot, The Netherlands). The ion exchang-
ers were equilibrated at physiological calcium (1.20 mmol/L) 
and magnesium (0.45 mmol/L) concentrations and a low so-
dium (122  mmol/L) concentration, to prevent calcium and 
magnesium adsorption and sodium release by the cation 
exchanging PS- DVB sulfonate, respectively, as previously 
demonstrated.15 FX CorDiax 50 dialyzers (1.0 m2) were 
purchased from Fresenius Medical Care (Bad Homburg, 
Germany). Thomas peristaltic pumps were obtained from 
Gardner Denver Thomas (Sheboygan, WI). Human uremic 
plasma was obtained by therapeutic plasmapheresis of a pa-
tient with ESKD. Peritoneal effluent (Extraneal 7.5%, Baxter, 
McGaw Park, Illinois) was obtained from 3 different patients 
after an intraperitoneal dwell time of ~12 hours. Ethical ap-
proval for this study was waived by the medical research 
ethics committee Utrecht because the use of anonymized left-
over bodily materials for scientific purposes does not comply 
with the Medical Research Involving Human Subjects Act 
(WMO) if patients’ consent is obtained.
2.2 | Experimental setup: 
Electrooxidation of uremic plasma
A dialysis circuit was built consisting of a plasma and di-
alysate circuit separated by a high- flux dialyzer (FX CorDiax 
50), a reservoir with 2 L of human uremic plasma, and 2 pumps 
(Figure 1). The dialysate circuit contained an EO unit, 150 g 
of PS- DVB sulfonate beads, and 75 g of iron oxide hydrox-
ide beads. At the start of the experiment, the dialysate circuit 
contained 200 mL of dialysate ([Na+] 100 mmol/L, [Mg2+] 
0.45 mmol/L, [Ca2+] 1.10 mmol/L, [HCO−
3
] 28 mmol/L, and 
[Cl−] 75  mmol/L). A current of 3 A was applied per unit, 
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corresponding with a current density of 3.3 mA/cm2, based 
on our previous observation that this resulted in efficient urea 
degradation and acceptable chlorine release.2 The applied 
voltage was 3.2 V. AC (150 g) was placed downstream of the 
EO unit in series as this was shown to significantly reduce 
chlorine concentrations to levels below the maximum allow-
able level as defined in the AAMI standards for dialysate 
used in standard HD.2 EO was turned on after the first hour 
and applied for 7 hours, in total 21 Ah for 2 L plasma. A de-
gassing unit was placed downstream of the EO unit (before 
the AC) to allow gasses formed during EO to escape.
2.3 | Experimental setup: 
Electrooxidation of peritoneal effluent
Two dialysis setups, similar to the dialysis circuit used for 
uremic plasma, were built for the treatment of 5 L of perito-
neal effluent with EO on (Figure 2A) and EO off (Figure 2B). 
To achieve clinically relevant urea, potassium and phosphate 
removal, both systems were upscaled. The new EO- on sys-
tem comprised 2 EO units with a cumulative surface area of 
2093 cm2, 300- 400 g of PS- DVB sulfonate beads, 100- 160 g 
of iron oxide hydroxide beads, and 240 and 720 g of AC up- 
and downstream of the EO units in series, respectively. A 
current of 3 A was applied per unit, corresponding with a 
current density of 2.9 mA/cm2 to treat the dialysate, again for 
7 hours, in total 42 Ah for 5 L dialysate. The applied volt-
age was 3.2 V per unit (connected in parallel). The sorbent 
cartridge of the new EO- off system comprised 300- 400 g of 
PS- DVB sulfonate beads, 100- 160 g of iron oxide hydroxide 
beads, and 1730- 3000 g of AC to achieve comparable urea 
removal as with the EO- on system. At the start of the experi-
ment, the dialysate circuit of both setups contained 600 mL 
of dialysate ([Na+] 100  mmol/L, [Mg2+] 0.45  mmol/L, 
[Ca2+] 1.10 mmol/L, [HCO−
3
] 28 mmol/L, [Cl−] 75 mmol/L, 
and glucose 278 mmol/L). This high glucose concentration 
(5%) was used to preload AC with glucose to establish glu-
cose release into the dialysate to obtain a high osmolality of 
the peritoneal dialysate, required to remove excess water via 
F I G U R E  1  Experimental setup for uremic plasma experiments. Human uremic plasma was continuously recirculated for 8 hours from a 
reservoir through a high- flux dialyzer, and dialysate was circulated in countercurrent direction through a circuit containing an electrooxidation (EO) 
unit (containing iron oxide hydroxide and poly(styrene- divinylbenzene) sulfonate beads for phosphate and potassium removal) in series with a 
degasser downstream and activated carbon (AC) (downstream of the degasser). During EO experiments, the EO unit was turned on after 1 hour
F I G U R E  2  Experimental setup for peritoneal effluent experiments. Peritoneal effluent was continuously recirculated from a reservoir 
through a high- flux dialyzer for 8 hours. In setup A (electro- oxidation [EO] on), peritoneal effluent was recirculated in countercurrent direction 
through a circuit containing an EO unit (containing iron oxide hydroxide and poly(styrene- divinylbenzene) sulfonate beads for phosphate and 
potassium removal) in series with a degasser and activated carbon (AC) (downstream of the degasser). In setup B (EO off), peritoneal effluent was 
recirculated in countercurrent direction through a circuit containing AC, iron oxide hydroxide beads, and poly(styrene- divinylbenzene) sulfonate 
beads. In setup A, the EO unit was turned on after 1 hour
(A) (B)
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osmosis from the patient during PD in vivo. Since EO was 
switched on after 1  hour, dialysate glucose concentrations 
during EO were lower (max ~100 mmol/L, see Figure 3D).
Human uremic plasma or peritoneal effluent was recircu-
lated for 8 hours at a flow rate of ~140 mL/min and ~125 mL/
min, respectively, through a high- flux dialyzer. Of note, these 
were the maximum flow rates that could be achieved with 
the Thomas pump which were used at the same settings for 
both experiments. The lower flow rate during the peritoneal 
effluent may be due to higher flow resistance in the dialyzer 
resulting from fibrin deposition or other small changes in the 
fluidic circuit, that is, the length or the diameter of the con-
necting tubing. A higher fluidic resistance requires a higher 
pressure drop to maintain the same flow rate. In this case, it 
is likely that the pump could not provide the necessary pres-
sure, resulting in a different flow rate between the experiments. 
Dialysate was circulated in countercurrent direction at a flow 
rate of 70- 80 mL/min over the EO unit and sorbents with EO 
on (n = 3) or EO off (n = 3) for comparison. Urea concentra-
tion in uremic plasma and peritoneal effluent at the start of the 
experiment was 20 ± 2.0 mmol/L. The EO unit was turned on 
after 1 hour to allow for saturation of AC upstream of the EO 
unit with urea, and urea was spiked every 1- 2 hours into the 
reservoir to prevent depletion of urea at the electrode and there-
with avoid side reactions. This approach resulted in relatively 
stable urea concentrations (Figure  S2). Samples were taken 
from the plasma or peritoneal effluent reservoir before the start 
and hourly during treatment for the wound closure assay and 
for the measurement of urea, glucose, GO, MGO, and 3- DG. 
Samples were stored at −80℃ until measurement of GDPs.
2.4 | Measurement of glucose 
degradation products
Samples for analysis of GDPs were stored at −80℃ until 
analyses. Ultraperformance LC- tandem MS (UPLC- MS/MS) 
was used to measure concentrations of GO, MGO, and 3- DG 
in plasma and peritoneal effluent as described.16
2.5 | Statistical analysis
One- way ANOVA for repeated measures with post- hoc 
Tukey test for multiple comparisons was used to analyze the 
difference in cell migration capacity and the concentration of 
F I G U R E  3  Concentrations of glucose degradation products (GDPs) (µmol/L; A, B) and glucose (mmol/L; C, D) in regenerated uremic plasma 
(A, C) and peritoneal effluent (B, D). GO, glyoxal; MGO, methylglyoxal; 3- DG, 3- deoxyglucosone. Solid line: EO on; dashed line: EO off. The 
mean ± SD of 3 experiments is presented. Of note, glucose concentration in uremic plasma (C) decreased during the first hour due to glucose 
adsorption by activated carbon, after which equilibration occurred at a glucose concentration of ~6 mmol/L, whereas in peritoneal effluent (D), 
glucose concentration increased due to glucose release by activated carbon which was preloaded with glucose at 278 mmol/L [Color figure can be 
viewed at wiley onlin elibr ary.com]
   | 5ELECTROOXIDATION FOR A WEARABLE ARTIFICIAL KIDNEY
GDPs in samples during treatment with EO on and EO off. 
A P value of <.05 was considered to be significant. Analyses 
were performed with GraphPad Prism 7.04 (GraphPad 
Software, La Jolla, California).
3 |  RESULTS
3.1 | Formation of glucose degradation 
products
GO and MGO concentrations increased 26- and 11- fold, re-
spectively, in uremic plasma (at [glucose] 7  mmol/L) and 
209- and 353- fold, respectively, in peritoneal effluent (at 
[glucose] 100 mmol/L) during treatment with EO, whereas 
no change was observed in GO and MGO concentrations in 
plasma or peritoneal effluent that was circulated through a 
dialysate circuit without EO (Figure 3). No change in 3- DG 
concentrations was observed in uremic plasma or peritoneal 
effluent during treatment with or without EO.
4 |  DISCUSSION
Our study shows that electrochemical dialysate regeneration 
with the current setup using graphite electrodes combined 
with AC is not safe due to the formation of GDPs which are 
not biocompatible. GO and MGO concentrations increased 
considerably in regenerated peritoneal effluent at supraphysi-
ological glucose concentrations during dialysis against elec-
trochemically regenerated dialysate and to a lesser extent in 
uremic plasma at physiological glucose concentrations.
Little is known about the safety of EO. Only 2 studies re-
port on the short- term safety of EO in vivo, while data on 
the composition of EO- treated dialysate and biocompatibility 
in vitro are scarce. Schueneman et al found that daily intra-
peritoneal injection of human hemofiltration regenerated by 
AC combined with EO, in rats (n = 18) for 20 d, was well 
tolerated without histopathological signs of organ toxicity.17 
In addition, hemofiltration of 3 minipigs (n = 3 sessions in 
4 d), using EO- regenerated hemofiltration or Ringer's lactate 
as a substitution fluid, did not result in a change in vital pa-
rameters (blood pressure, heart rate, pO2, and pCO2) or blood 
hematology and biochemistry (white blood count, hemoglo-
bin levels, alkaline phosphatase, aspartate aminotransferase, 
and total protein).17 Although bicarbonate and pH tended to 
decline with EO- regenerated hemofiltration, this could be 
attributed to not- EO- related bicarbonate removal during di-
alysate regeneration. Our group evaluated a miniature dial-
ysis device, identical to the device used in the present study 
for plasma experiments, with continuous dialysate regener-
ation using EO in combination with AC and ion exchangers 
in vitro and healthy goats.9,11 In vitro, treatment of dialysate 
or uremic plasma with this device did not affect total antiox-
idant capacity, intracellular ROS generation, cell viability, or 
cell proliferation compared to treatment with AC without EO. 
For the in vivo evaluation, 16 dialysis experiments of 3 hours 
were performed (~2/mo) in healthy goats.9 Although vital pa-
rameters remained stable during dialysis and no changes in 
blood hematology or biochemistry occurred that were related 
to EO, ammonium was released and chlorine concentrations 
exceeded acceptable levels at higher dialysate flow rates. 
GDPs were not measured. Thus, no manifest toxicity was 
observed during these preliminary safety studies. However, 
the duration of exposure to EO- treated fluids was short. 
Insufficient evidence exists on degradation products and 
(long term) safety of electrochemical dialysate regeneration.
GO (58 Da) and MGO (72 Da) are dicarbonyl compounds 
that can be formed during oxidative degradation of glucose. 
In patients with ESKD, GO, and MGO plasma concentra-
tions are ~3- fold higher compared with healthy controls18 and 
have been associated with endothelial dysfunction, inflam-
mation, and deterioration of CKD.19,20 Thus, the observation 
that GO and MGO are formed during EO of uremic plasma 
and dialysate is a concern. In comparison, concentrations of 
GO and MGO in EO- treated uremic plasma were ninefold 
and fourfold higher, respectively, than plasma concentra-
tions in dialysis patients treated with HD.18 Furthermore, to 
achieve clinically relevant urea removal, continuous treat-
ment (24 h/d) with 2 EO units or intermittent treatment with 
6 EO units for 8  h/d is required,9 further increasing GDP 
formation. GO and MGO concentrations in EO- treated peri-
toneal effluent were ~220- 660- fold and ~27- 46- fold higher, 
respectively, than concentrations in commercial PD flu-
ids containing glucose 1.5%- 4.25%.21,22 GDPs in glucose- 
containing PD fluids are formed during heat sterilization and 
storage and are associated with functional and morphological 
changes of the peritoneal membrane in vitro and in vivo.23- 29 
Theoretically, glucose oxidation is likely to occur because 
glucose is abundantly present in the dialysate, in particular 
in peritoneal dialysate, and glucose may be oxidized at a rel-
atively low redox potential. In accordance with this, several 
studies observed substantial glucose degradation during elec-
trochemical dialysate treatment30- 32 and suggest that glucose 
was oxidized to gluconic acid, a nontoxic monocarboxylic 
acid.30,31 Electrocatalytic oxidation of glucose in pH neutral 
solutions on catalytic surfaces (eg, platinum, gold, or copper 
electrodes) yielded gluconic acid, gluconolactone, carbon 
monoxide, and carbon dioxide at potentials <1.4 V versus a 
Reversible Hydrogen reference Electrode (RHE) and glucaric 
acid, oxalic acid, formic acid, tartaric acid, and glycolic acid 
at higher potentials up to 1.8 V versus RHE.33,34 Because our 
EO device is current- driven, it is difficult to compare reaction 
products in our setup with potential- driven EO experiments 
in the literature. However, it is likely that at the relatively high 
voltage of ~3.2 V, as applied in the present study, glucose and 
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its reaction products are oxidized at the electrode interface to 
form GO and MGO.35
As GDPs were not removed by AC downstream of the EO 
unit, other methods must be explored to prevent their release 
into the patient. For example, the addition of a dicarbonyl 
“scavenger” such as 2- hydroxybenzylamine or an antioxi-
dant, for example, ascorbic acid or N- acetylcysteine, down-
stream of the EO unit may remove or neutralize dicarbonyl 
compounds.30,36- 38 Because GO and MGO formation was 
much lower during EO of uremic plasma compared with peri-
toneal effluent due to lower glucose concentration in plasma, 
it may initially be more feasible to reduce the formation or 
neutralize the effects of GO and MGO in an HD- based WAK 
than in a PD- based WAK.
The main limitation of this study is that we only measured 
3 GDPs, while other glucose oxidation products or other un-
known potentially toxic oxidative by- products may be formed. 
Extensive biocompatibility testing of the EO technique will 
be performed after the GDP issues have been solved.
In conclusion, EO is currently not safe for dialysate re-
generation in a WAK for either HD or PD due to glucose ox-
idation yielding toxic compounds. Future studies must focus 
on strategies to prevent GDP formation or, once formed, to 
neutralize their toxic effects.
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